|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114791 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-17 17:00:47 |
|
注册时间: Date of Registration: |
2025-12-17 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超声造影定量分析移植肾早期并发症参数改变的多中心研究 |
|
Public title: |
Multicenter Study on Quantitative Analysis of Parameter Changes in Early Complications of Renal Transplant Using Contrast-Enhanced Ultrasound |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超声造影定量分析移植肾早期并发症参数改变的多中心研究 |
|
Scientific title: |
Multicenter Study on Quantitative Analysis of Parameter Changes in Early Complications of Renal Transplant Using Contrast-Enhanced Ultrasound |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐楠 |
研究负责人: |
曹军英 |
|
Applicant: |
Xu Nan |
Study leader: |
Cao Junying |
|
申请注册联系人电话: Applicant telephone: |
+86 180 5549 2694 |
研究负责人电话:
Study leader's |
+86 177 9099 1799 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1208819884@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
shenzongchaosheng@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市玄武区中山东路305号 |
研究负责人通讯地址: |
江苏省南京市玄武区中山东路305号 |
|
Applicant address: |
No. 305, Zhongshan East Road, Nanjing, Jiangsu |
Study leader's address: |
No. 305, Zhongshan East Road, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
东部战区总医院 |
||
|
Applicant's institution: |
Eastern Theater Command General Hospital |
||
|
研究负责人所在单位: |
东部战区总医院 |
||
|
Affiliation of the Leader: |
Eastern Theater Command General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025DZKY-122-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
东部战区总医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
The Clinical Research Ethics Committee of the Eastern Theater Command General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-24 00:00:00 | ||
|
伦理委员会联系人: |
刘玉秀 |
||
|
Contact Name of the ethic committee: |
Liu Yuxiu |
||
|
伦理委员会联系地址: |
江苏省南京市玄武区中山东路305号 |
||
|
Contact Address of the ethic committee: |
No. 305, Zhongshan East Road, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 5204 3658 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
东部战区总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Eastern Theater Command General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市玄武区中山东路305号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 305, Zhongshan East Road, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
东部战区总医院2024年度院内课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
2024 Annual In-Hospital Research Projects of the Eastern Theater Command General Hospital |
||||||||||||||||||||||
|
研究疾病: |
移植肾早期并发症 |
||||||||||||||||||||||
|
Target disease: |
Early complications of transplanted kidney |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
明确超声新技术(包括超声造影及超分辨显微成像)的各定量参数在监测移植肾术后早期并发症中的最佳参数并评估其应用价值,评估超声新技术在移植肾早期并发症诊断中的敏感性和特异性。建立基于超声造影及超分辨显微成像各定量参数的综合预测模型,并与临床指标模型进行对比,评估超声新技术定量参数模型在移植肾术后早期并发症中预测价值。探讨如何将该模型应用于临床实践,以提高移植肾患者的预后和生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
To identify the optimal quantitative parameters of novel ultrasound techniques, including contrast-enhanced ultrasound and super-resolution microimaging, for monitoring early postoperative complications following kidney transplantation, and to evaluate their application value. This involves assessing the sensitivity and specificity of these novel ultrasound techniques in diagnosing early complications of the transplanted kidney. Furthermore, a comprehensive predictive model integrating quantitative parameters from both contrast-enhanced ultrasound and super-resolution microimaging will be established and compared with a clinical indicator model to evaluate the predictive value of the quantitative parameter model based on novel ultrasound techniques for early post-transplant complications. Finally, the study will explore strategies for implementing this model into clinical practice to improve the prognosis and quality of life of kidney transplant recipients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18 岁; (2)患者在肾穿刺活检前后一周内行常规超声、超声造影检查; (3)经穿刺活检明确肾实质病变类型或CTA、MRA或DSA检查明确血管并发症类型; (4)有完整的病史信息、临床检验结果和影像图像资料; (5)能够理解并愿意签署知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age >= 18 years; 2.Patients underwent conventional ultrasound and contrast-enhanced ultrasound examinations within one week before and after renal biopsy; 3.The type of renal parenchymal lesion was confirmed by biopsy, or the type of vascular complication was confirmed by CTA ,MRA or DSA examination; 4.Complete medical history, clinical laboratory results, and imaging data are available; 5.Ability to understand and willingness to sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)合并有严重心肺疾病患者; (2)可能存在造影剂过敏或其他禁忌症; (3)因呼吸运动等配合不佳患者; (4)原发病史等临床资料不全者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with severe comorbid cardiopulmonary diseases; 2.Possible allergy to contrast agents or other contraindications; 3.Patients with poor cooperation (e.g., due to respiratory motion); 4.Patients with incomplete clinical data (e.g., primary disease history). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究将采用预先设计好的病例记录表来收集所有受试者的数据,CRF将包含人口学资料、病史、实验室检查、超声定量指标、病理结果等,操作者将遵循标准操作规程,确保数据准确、完整,任何更正都将留有痕迹。本研究将采用ResMan进行数据的电子采集与管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study will utilize pre-designed Case Report Forms (CRFs) to collect data from all study participants. The CRFs will encompass demographic information, medical history, laboratory test results, quantitative ultrasound parameters, pathological findings, etc. Operators will adhere to Standard Operating Procedures (SOPs) to ensure the accuracy and completeness of data, with any corrections retaining an audit trail. This study will employ the ResMan system for electronic data capture (EDC) and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |